Reduced Neutralization of SARS-CoV-2 Omicron Variant in Sera from SARS-CoV-1 Survivors after 3-dose of Vaccination
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Recent studies found that Omicron variant escapes vaccine-elicited immunity. Interestingly, potent cross-clade pan-sarbecovirus neutralizing antibodies were found in survivors of the infection by SARS-CoV-1 after BNT162b2 mRNA vaccination ( N Engl J Med. 2021 Oct 7;385(15):1401-1406 ). These pan-sarbecovirus neutralizing antibodies were observed to efficiently neutralize the infection driven by the S protein from both SARS-CoV and multiple SARS-CoV-2 variants of concern (VOC) including B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). However, whether these cross-reactive antibodies could neutralize the Omicron variant is still unknown. Based on the data collected from a cohort of SARS-CoV-1 survivors received 3-dose of immunization, our studies reported herein showed that a high level of neutralizing antibodies against both SARS-CoV-1 and SARS-CoV-2 were elicited by a 3rd-dose of booster vaccination of protein subunit vaccine ZF2001. However, a dramatically reduced neutralization of SARS-CoV-2 Omicron Variant (B.1.1.529) is observed in sera from these SARS-CoV-1 survivors received 3-dose of Vaccination. Our results indicates that the rapid development of pan-variant adapted vaccines is warranted.
Article activity feed
-
SciScore for 10.1101/2022.05.21.492903: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical statement: The study protocol was approved by the Ethics Committee of the Institute of Beijing Ditan Hospital, Capital Medical University (IRB#2021-(024)-02).
Consent: Written informed consent was obtained from all participants before the enrollment.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources HEK-293T cells were transfected with the plasmids expressing different S protein respectively. HEK-293Tsuggested: NoneRecombinant DNA Sentences Resources Cell transfection and pseudotyped virus production: The pSectag2 … SciScore for 10.1101/2022.05.21.492903: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical statement: The study protocol was approved by the Ethics Committee of the Institute of Beijing Ditan Hospital, Capital Medical University (IRB#2021-(024)-02).
Consent: Written informed consent was obtained from all participants before the enrollment.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources HEK-293T cells were transfected with the plasmids expressing different S protein respectively. HEK-293Tsuggested: NoneRecombinant DNA Sentences Resources Cell transfection and pseudotyped virus production: The pSectag2 vector was used to construct recombinant plasmid of codon optimized spike proteins of SARS-CoV-2 prototype (Wuhan-1 reference strain containing D614G mutation) and variants, with a 19 amino acid truncation at the C-terminus of the spike protein1 (with mutations shown in Fig. pSectag2suggested: NoneSoftware and Algorithms Sentences Resources pVNT50 was interpolated from the neutralization curves determined using the log(inhibitor) vs. normalized response -- Variable slope fit using automatic outlier detection in GraphPad Prism Software. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-